[A15-59] Crizotinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2016
Project no.:
A15-59
Commission:
Commission awarded on 21.12.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-59 | Crizotinib (lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-41 | Crizotinib (NSCLC) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A16-26 | Crizotinib - Addendum to Commission A15-59 | Commission completed |
| A12-15 | Crizotinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2016-06-16 A G-BA decision was published.